The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Safety concerns of using HER2-targeting therapies in gastrointestinal cancers
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, addresses safety considerations when utilizing HER2-directed therapies in gastrointestinal cancers. While rare, there is a risk of developing interstitial lung disease (ILD) with trastuzumab deruxtecan. Prompt recognition of grade 1 toxicity symptoms is crucial, following clinical guidelines that recommend discontinuing treatment until ILD resolves to grade 0, followed by corticosteroids. Escalation to grade 2 toxicity necessitates discontinuation of trastuzumab deruxtecan. Managing other toxicity symptoms such as nausea and vomiting with anti-emetic medications is feasible, but maintaining the balance between symptom relief and preserving the efficacy of anticancer treatment remains pivotal. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
